Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Employment agrmnt
Quarterly results
Auditor change
Consulting agrmnt
|
|
PIERIS PHARMACEUTICALS, INC. (PIRS)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 05/10/2023 |
8-K
| Quarterly results|
Docs:
|
"Three Months Ended March 31, 2023 2022 Revenues $ 1,936 $ 10,988 Operating expenses Research and development 13,424 14,066 General and administrative 4,023 4,379 Total operating expenses 17,447 18,445 Loss from operations Interest income 357 Grant income 2,028 2,130 Other income , net (57 229 Net loss",
"Investor Presentation, dated May 2023" |
|
| 08/04/2022 |
8-K
| Quarterly results |
| 05/11/2022 |
8-K
| Quarterly results |
| 03/01/2022 |
8-K
| Quarterly results |
| 11/02/2021 |
8-K
| Quarterly results |
| 08/04/2021 |
8-K
| Quarterly results |
| 05/17/2021 |
8-K
| Quarterly results |
| 03/30/2021 |
8-K
| Quarterly results |
| 11/04/2020 |
8-K
| Quarterly results |
| 08/10/2020 |
8-K
| Quarterly results |
| 05/11/2020 |
8-K
| Quarterly results |
| 03/12/2020 |
8-K
| Quarterly results |
| 11/12/2019 |
8-K
| Quarterly results |
| 08/01/2019 |
8-K
| Quarterly results |
| 05/10/2019 |
8-K
| Quarterly results |
| 03/12/2019 |
8-K
| Quarterly results|
Docs:
|
"PIERIS PHARMACEUTICALS REPORTS 2018 YEAR-END CASH POSITION AND PROVIDES CORPORATE UPDATE COMPANY TO HOST AN INVESTOR CONFERENCE CALL ON TUESDAY, MARCH 12, 2019 AT 8:00 AM EDT BOSTON, MA, March 12, 2019 - Pieris Pharmaceuticals, Inc. , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin ® technology platform for respiratory diseases, cancer and other indications, today reported its cash position for the fiscal year ended December 31, 2018 and provided an update on the Company’s recent and future developments. “2018 was an important year for the development of our two core franchises: respiratory diseases and immuno-oncology. On the respiratory front, we announced that PRS-060, an inhaled IL-4 receptor alpha antagonist for moderate-to-seve..." |
|
| 11/07/2018 |
8-K
| Quarterly results |
| 08/09/2018 |
8-K
| Quarterly results|
Docs:
|
"PIERIS PHARMACEUTICALS REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE COMPANY TO HOST AN INVESTOR CONFERENCE CALL ON THURSDAY, AUGUST 9, 2018 AT 8:00 AM EDT BOSTON, MA, August 9, 2018 - Pieris Pharmaceuticals, Inc. , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin ® technology platform for cancer, respiratory and other diseases, today reported financial results for the second quarter of 2018 ended June 30, 2018, and provided an update on the Company's recent and future developments. “The second quarter of 2018 was characterized by intense focus on execution of our clinical programs. We remain on track to update investors with data from all three programs before year end. Our lead IO program, PRS-343, cont..." |
|
| 05/10/2018 |
8-K
| Quarterly results |
| 03/09/2018 |
8-K
| Quarterly results |
| 11/08/2017 |
8-K
| Quarterly results |
| 08/09/2017 |
8-K
| Quarterly results |
| 05/11/2017 |
8-K
| Form 8-K - Current report |
| 03/22/2017 |
8-K
| Quarterly results|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : March 22, 2017 PIERIS PHARMACEUTICALS, INC. Nevada 001-37471 EIN 30-0784346 255 State Street, 9th Floor Boston, MA United States Registrant's telephone number, including area code: 857-246-8998 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-...",
"PIERIS PHARMACEUTICALS REPORTS FULL-YEAR 2016 FINANCIAL RESULTS AND CORPORATE UPDATE COMPANY TO HOST AN INVESTOR CONFERENCE CALL ON THURSDAY, MARCH 23, 2017 AT 10:00 AM EDT BOSTON, MA, March 22, 2017 - Pieris Pharmaceuticals, Inc. , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer and other diseases, today reported financial results for the fourth quarter and fiscal year of 2016 and provided an update on the Company's recent developments. “2016 was a highly productive year for Pieris marked by: i) broad advancement of our proprietary clinical and preclinical programs, ii) completion of a $16.5 million private placement financing that strengthened our shareholder base, iii) achievement of several milesto..." |
|
| 11/10/2016 |
8-K
| Form 8-K - Current report |
| 08/11/2016 |
8-K
| Form 8-K - Current report |
| 05/12/2016 |
8-K
| Quarterly results |
| 11/12/2015 |
8-K
| Quarterly results |
| 08/13/2015 |
8-K
| Quarterly results |
| 05/14/2015 |
8-K
| Quarterly results |
|
|